AVTR Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $1.62 billion, down 5% year-over-year on an organic basis, primarily due to weaker lab performance.

Adjusted EBITDA Margin: 16.5%, with adjusted EBITDA of $268 million.

Adjusted EPS: $0.22, a decline of $0.04 year-over-year.

Free Cash Flow: $172 million, with an adjusted conversion rate of 124%.

Adjusted Gross Profit: $527 million, reflecting a 32.4% adjusted gross margin, down 100 basis points year-over-year.

Goodwill Impairment: $785 million related to the lab distribution business due to ongoing margin pressures and share price decline.

Net Leverage: 3.1x adjusted EBITDA, down from Q2.

2Strategic Updates and Business Highlights

Leadership Transition: Emmanuel Ligner, new CEO, emphasizes the need for operational improvement and strategic focus.

Avantor Revival Plan: A new initiative focusing on five key pillars: go-to-market strategy, manufacturing and supply chain investment, portfolio scrutiny, cost savings, and talent enhancement.

Customer Engagement: Emphasis on empowering commercial teams and improving customer service, particularly through e-commerce enhancements.

Share Repurchase Program: $500 million authorized to demonstrate confidence in long-term business value.

3Forward Guidance and Outlook

Full Year 2025 Guidance: Organic revenue growth revised to negative 3.5% to negative 2.5%, with reported revenue growth expected to be negative 4% to negative 3%.

Segment Expectations:

Laboratory Solutions: Anticipated revenue decline of mid-single digits to low single digits.

Bioscience Production: Expected organic revenue growth of low single digits, with Q4 performance anticipated to decline further.

Adjusted EPS Guidance: Reduced to between $0.88 and $0.92.

Free Cash Flow: Expected to be $550 million to $600 million before one-time costs.

4Bad News, Challenges, or Points of Concern

Weak Lab Performance: Continued share losses and declining customer activity, particularly in lab services and consumables, attributed to market uncertainty and competitive pressures.

Operational Headwinds: Challenges in manufacturing and supply chain affecting throughput and service levels, particularly in bioprocessing.

Goodwill Impairment: Significant non-cash charge reflecting ongoing struggles in the lab distribution business.

Market Uncertainty: Ongoing concerns regarding basic research funding and potential impacts from the U.S. federal government shutdown.

5Notable Q&A Insights

Confidence in Fixing Issues: Emmanuel Ligner expressed confidence that the challenges are fixable, emphasizing the need for improved leadership and accountability.

Market Share Dynamics: Discussion on the loss of key accounts and the time required to regain share, with a focus on stabilizing the lab business.

Pricing Strategy: Clarification that Avantor is committed to improving pricing while managing inflation and cost pressures.

Investment Rationale: Ligner justified the share buyback as a demonstration of confidence in the company’s long-term value despite current challenges.

Operational Improvements: Insights into the need for strategic investments in manufacturing and supply chain to enhance service levels and reliability. Overall, the call highlighted a mix of operational challenges and strategic initiatives aimed at revitalizing Avantor's performance, with a clear commitment from leadership to address the underlying issues affecting the business.